Overview

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Alexion Pharmaceuticals
Treatments:
Eculizumab